Re: arna soars on jpm analysis. eom
"Which Beats a sharp stick in the eye and the xbi and ibb performance handedly." Let's make no mistake I"m way long. The stick is still stuck in my head from the recent drop of the +$60 value. If I look further back than that this conversation becomes even less productive.
This is R&D biotech, speculation normally holds weight (value) offset by the doubt of the resources to see it through. In this case the resources are present but it seems Wall Street doesn't trust the keeper of the purse strings. Stockholders have not been given priority. I'll stay with merely buoyed until we're back over +$60 and we pass the next speech of someone being excited about their own prospects instead of that of the common stockholders.
Wall street is holding his feet to the fire until value improves. If this were a privately held company I'm sure incentives would be more conservative.